5. Metabolomics as Complementary Diagnostics – Closer to Function
Metabolomics measures not who is present in the gut but what they produce — capturing function directly, not just microbiome composition.
What is metabolomics, and why is it different from sequencing?
16S and shotgun analyses measure the microbiome's composition: who is present in the gut. Metabolomics, by contrast, measures the microbiome's function: the metabolic products produced by microbes (and, to a lesser extent, the host). Short-chain fatty acids (butyrate, propionate, acetate), bile acid metabolites, tryptophan breakdown products, polyamines, indoles – these are the molecules that actually "do" something in the body: nourishing the gut wall, modulating the immune system, influencing brain function, and determining inflammatory status [24].
This fundamental difference is clinically decisive: microbiome composition alone does not confirm that a given function is occurring. The presence of a butyrate-producing bacterium does not guarantee that sufficient butyrate is being produced – for that, the appropriate substrate (fibre), appropriate pH, appropriate competitive environment, and active gene expression are all required. Metabolomics, by contrast, directly measures the end product: not only whether the "factory" is there, but whether it is producing [25].
How is metabolomic analysis performed?
The most common clinical metabolomics platforms use mass spectrometry (MS) and nuclear magnetic resonance spectroscopy (NMR) [25] – typically from stool, serum, or urine. The analysis can simultaneously measure hundreds to thousands of metabolites, which are then grouped and interpreted using bioinformatic tools. Untargeted metabolomics records all detectable molecules; the targeted approach focuses on a pre-defined metabolite panel.
The method's advantages are real: it provides direct functional information, does not require DNA amplification (so the biases of amplicon sequencing do not apply), and builds on MS platforms already routinely used in clinical laboratories. NMR-based metabolomics is particularly reproducible and inter-laboratory comparable, since the physical measurement principle is less dependent on reagent kits [25].
Limitations and interpretive challenges
- Not microbiome-specific: Some of the metabolites measured in stool and serum also originate from the host's own metabolism, diet, and medications. Distinguishing "microbiome origin" is not always possible [25].
- Snapshot in time: Metabolite levels change rapidly – eating, physical activity and stress can influence results within hours. A single measurement provides a snapshot, not a stable characteristic [26].
- Incomplete databases: The biological function of a significant proportion of detected metabolites is still unknown. The proportion of "unknown peaks" in untargeted analyses ranges from 30–60% – about which we currently cannot say anything [25].
- No validated clinical reference ranges: Just as with sequencing, metabolomics lacks a reference calibrated to the individual, their diet, age and health status. Defining a "normal" butyrate level is just as context-dependent as defining a "normal" microbiome composition [26].
- Interpolation and model-based inferences: Functional pathway reconstructions (e.g. estimating microbial metabolic pathways from metabolite data) also contain algorithmic interpolation – missing measurement points are ""filled in" by the model based on known biochemical relationships [25], [24].
Connection to FMT and clinical applicability
In FMT, metabolomics is a particularly promising complementary tool. The success of transplantation is signalled not only by the appearance of donor strains but by the restoration of the functional metabolite profile: rising faecal butyrate, normalising bile acid metabolites, decreasing inflammatory indicators. In some research protocols these have already been measured, finding that metabolomic "normalisation" correlates better with clinical improvement than changes in taxonomic composition [25], [26], [28].
In clinical routine, however, metabolomics has not yet reached where sequencing stands [25], [24] – that is, widely commercially available but limited in clinical decision support. The reasons are partly the higher cost and lack of platform standardisation, and partly the underdevelopment of the interpretive framework. The direction of development is clearly towards the combined, multi-omics application of metabolomics and microbiome sequencing – where composition and function become visible simultaneously.
References
[24] Sonnenburg JL, Bäckhed F. Diet–microbiota interactions as moderators of human metabolism. Nature. 2016. Link
Review of mechanisms linking the gut microbiota to obesity and type 2 diabetes drawing on translational animal models and human studies. The microbiota emerges as a mediator of dietary impact on host metabolic status, with growing efforts to establish causal relationships in people and develop therapeutic interventions including personalised nutrition.
[25] Zierer J, Jackson MA, Kastenmüller G et al. The fecal metabolome as a functional readout of the gut microbiome. Nat Genet. 2018. Link
Comprehensive analysis of 1,116 metabolites from 786 individuals in the TwinsUK population-based twin study showed that the faecal metabolome is only modestly heritable (H2 = 17.9%), with one replicated locus at NAT2 associated with faecal metabolic traits. The faecal metabolome largely reflects gut microbial composition, explaining on average 67.7% (+/-18.8%) of its variance, and is strongly associated with visceral fat mass. Findings position faecal metabolomics as a functional readout linking microbiome composition to abdominal obesity.
[26] Dahl WJ, Zhu H, Guan LL. Fecal metabolomics reveals diet-dependent microbiome changes. Curr Dev Nutr. 2020. Link
Dahl, Zhu and Guan summarize fecal metabolomics findings linking diet to microbiome-driven metabolic changes in this Current Developments in Nutrition conference abstract. They report that dietary intake, particularly carbohydrate quality and fiber type, alters fecal concentrations of short-chain fatty acids, bile acids and amino-acid–derived metabolites, with concomitant shifts in microbial composition. The work supports the view that fecal metabolomics is a useful intermediate readout connecting dietary intervention to host-relevant microbial outputs. Mechanistic interpretation focuses on saccharolytic versus proteolytic fermentation balance. The authors call for standardised metabolomic methods to compare across diet-microbiome trials.
[28] Vétizou M, Pitt JM, Daillère R et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015. Link
The antitumour effect of CTLA-4 blockade depends on specific Bacteroides species. In mice and patients, T-cell responses against B. thetaiotaomicron or B. fragilis correlated with treatment efficacy. Antibiotic-treated or germ-free mice did not respond to anti-CTLA-4, and the defect was rescued by B. fragilis gavage, polysaccharide immunisation, or transfer of B. fragilis-specific T cells. Faecal microbiota transplantation from humans to mice confirmed that CTLA-4 therapy in melanoma patients favours outgrowth of B. fragilis with anticancer activity.